Cancer Biomarkers
A section of Cancers (ISSN 2072-6694).
Section Information
In the current era of precision medicine, cancer biomarkers provide critical data for predicting responses to therapies, generating prognoses of disease outcomes, and in determining oncogenic risk. Biomarkers are increasingly important as companions for drug discovery and development, and can help guide clinical decision-making. This section of Cancers aims to rapidly publish contributions on all aspects of Cancer Biomarkers. We encourage the submission of manuscripts that provide novel biomarkers, systematic reviews, and papers that report significant advances in cancer biomarkers. Topics include, but are not limited to:
- Genomic signatures
- RNA biomarkers
- miRNA biomarkers
- DNA biomarkers
- Protein biomarkers
- Metabolomic biomarkers
- Mutational biomarkers
- Circulating tumor cell (CTC) biomarkers
- Cellular biomarkers
- Imaging biomarkers
- Clinical biomarkers
- Biomarkers of drug response
- Biomarkers of genetic predisposition to cancer
- Biomarkers of cancer outcomes
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Novel Diagnostic and Therapeutic Approaches in Diffuse Gliomas (Deadline: 15 October 2024)
- Genome Sequencing of Cancer: Identifying Targets and Biomarkers for Therapy (Deadline: 25 October 2024)
- Head and Neck Cancers—Novel Approaches and Future Outlook (Deadline: 31 October 2024)
- Cancer Biomarkers: Recent Progress, Innovations and Future Clinical Implications (Deadline: 15 November 2024)
- Novel Biomarkers of Hepatobiliary Tumors (Deadline: 30 November 2024)
- miRNA in Colorectal Cancer (Deadline: 30 November 2024)
- Possible Biomarkers in Oral Tumors and Their Clinical Significance (Deadline: 30 November 2024)
- Breast Cancer Biomarkers and Clinical Translation (Deadline: 30 November 2024)
- Liquid Biopsy in Breast Cancer (2nd Edition) (Deadline: 15 December 2024)
- New Biomarkers in Cancers 2nd Edition (Deadline: 15 December 2024)
- Brain Tumours: Advances in Imaging-Guided Diagnosis, Surveillance and Therapy (Deadline: 20 December 2024)
- Novel Prognostic Biomarkers in Human Cancers: From Discovery to Application (Deadline: 31 December 2024)
- Views and Perspectives of Cutaneous Squamous Cell Carcinoma (Deadline: 31 December 2024)
- Feature Papers in Section "Cancer Biomarkers" in 2023–2024 (Deadline: 31 December 2024)
- PTEN: Regulation, Signalling and Targeting in Cancer (Deadline: 31 December 2024)
- Monitoring Treatment Response of Biomarkers in Cancer (Deadline: 1 January 2025)
- Development, Validation and Application of Advanced Biomarkers in Cerebral Tumours (Deadline: 31 January 2025)
- New Approaches in Leukemia (Deadline: 31 January 2025)
- Glycosylation in Cancer—Biomarkers and Targeted Therapies (2nd Edition) (Deadline: 31 January 2025)
- Predictive Biomarkers for Lung Cancer (Deadline: 31 January 2025)
- Breast Cancer: Biomarkers of Diagnosis and Prognosis (Deadline: 15 February 2025)
- Predictive Biomarkers for Colorectal Cancer (Deadline: 21 March 2025)
- Ovarian Cancer Biomarkers, Diagnostic, and Therapeutic Technologies 2nd Edition (Deadline: 30 March 2025)
- The Estrogen Receptor and Its Role in Cancer (Deadline: 15 April 2025)
- Biomarkers of Ovarian Cancer Progression (Deadline: 30 April 2025)
- Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers (2nd Edition) (Deadline: 31 May 2025)
- Pre-clinical Studies of Personalized Medicine for Cancer Research (Deadline: 30 June 2025)
- Cancer Biomarkers—Detection and Evaluation of Response to Therapy (Deadline: 30 June 2025)
- Novel Biomarkers in Non-Small Cell Lung Cancer (NSCLC) (Deadline: 30 June 2025)
- Advances in Exosomes and Cancer Biomarkers (Deadline: 12 September 2025)
- Biomarkers for Treatment Prediction, Prognosis and Early Detection of Gynecologic Cancer (Deadline: 15 December 2025)
Topical Collections
Following topical collections within this section are currently open for submissions:
